原料药及中间体
- 分类:产品
- 发布时间:2021-06-07 17:47:33
- 访问量:0
概要:
详情
No. | Generic Name | Item/Code | CAS No. | Molecular structure | 治疗领域(用途) | 状态 |
1 | Atorvastatin Calcium 阿托伐他汀钙 |
ATS-8 | 125971-94-0 | 降血脂 | USA - US-FDA GMP approved - L1: USDMF No. 18835 - API: USDMF No. 26022 EU - CEP 2012-139/CEP 2022-466 Japan - MF: 227MF10255 Canada - L1: CA-DMF(2006-162) - L4: CA-DMF(2009-192) Korea -KDMF:20130618-132-H-238-23 China - API: 1, 国药准字H20103023 -CDE Registration No.:Y20190007449 登记状态:A |
|
M1 | 42558-54-3 | |||||
L1 | 125971-95-1 | |||||
API | 344423-98-9 | |||||
2 | Rosuvastatin Calcium 瑞舒伐他汀钙 |
R1 | 289042-12-2 | 降血脂 | USA - USDMF No. 25781 - US-FDA GMP approved EU -CEP 2020-243 Japan - MF: 227MF10120 China -CDE Registration No.:Y20210000578 登记状态:A |
|
R1.5 | 355806-00-7 | |||||
RJS3 | 147118-40-9 | |||||
API | 147098-20-2 | |||||
3 | Fluvastatin sodium 氟伐他汀钠 |
API | 93957-55-2 | 降血脂 | China -CDE Registration No.:Y20230001392 登记状态:I |
|
4 | Clopidogrel Hydrogen Sulfate 硫酸氢氯吡格雷 |
API | 135046-48-9 120202-66-6 |
抗血栓 | China -CDE Registration No.:Y20190001006 2 登记状态:A USA - USDMF No. 35081 Canada CA-DMF(2020-150) EU - CEP 2020-408 |
|
SM1 | 141109-14-0 | |||||
SM2 | 40412-06-4 | |||||
5 | Macitentan 马昔腾坦 |
API | 441798-33-0 | 肺动脉高压 | USA -USDMF No. 031658 China -CDE Registration No.:Y20190000010 登记状态:A |
|
6 | Betahistine Dihydrochloride 盐酸倍他司汀 |
API | 5579-84-0 | 美尼尔综合征 | China -CDE Registration No.:Y20200001060 登记状态:A |
|
7 | Selexipag 司来帕格 |
API | 475086-01-2 | 肺动脉高压 | China -CDE Registration No.:Y20230000520 登记状态:I |
|
8 | Ticagrelor 替格瑞洛 |
API | 274693-27-5 | 抗血栓 | China -CDE Registration No.:Y20190000753 登记状态:A |
|
9 | Rivaroxaban 利伐沙班 |
API | 366789-02-8 | 抗血栓 | China -CDE Registration No.:Y20210000022 登记状态:A EU -CEP 2021-142 |
|
10 | Doxazosin Mesylate 甲磺酸多沙唑嗪 |
Base | 74191-85-8 | 高血压 | China API: 国药准字H20050006 -CDE Registration No.:Y20190007511 登记状态:A Japan - MF: 218MF10823 |
|
API | 77883-43-3 | |||||
11 | Idelalisib 艾代拉里斯 |
API | 870281-82-6 | 抗肿瘤 | USA -USDMF No.32519 |
|
12 | Palbociclib 帕布昔利布 |
POB10 | 1013916-37-4 | 抗肿瘤 | PV Done | |
POB15 | 1016636-76-2 | PV Done | ||||
POB02 | 571188-59-5 | PV Done | ||||
API | 571190-30-2 | Lab Stage | ||||
13 | Pazopanib HCL 盐酸帕唑帕尼 |
PAZ20 | 635702-60-2 | 抗肿瘤 | Lab Stage | |
PAZ70 | 6973-09-7 | PV Done | ||||
API | 63570264-6 | USA -USDMF No.034146 |
||||
14 | Ponatinib HCL 盐酸泊那替尼 |
API | 1114544-31-8 | HCL | 抗肿瘤 | USA -USDMF No.035413 Canada HC MF # 2023-106 |
15 | Norfloxacin 诺氟沙星 |
Free Base | 70458-96-7 | 抗感染 | EU - CEP 2006-037 EUGMP:18MPP049HPT01 China - API: 国药准字H33021898 -CDE Registration No.:Y20190007457 登记状态:A Japan - MF: 226MF10208 Canada CA-DMF(2018-192) |
|
Nicotinate Salt | 118803-81-9 | |||||
16 | Vortioxetine HBr 氢溴酸伏硫西汀 |
API | 960203-27-4 | 抗抑郁 | China -CDE Registration No.:Y20230001182 登记状态:I USA -USDMF No. 038847 |
|
17 | Brivaracetam 布立西坦 |
API | 357336-20-0 |
抗癫痫 | China -CDE Registration No.:Y20220000078 登记状态:I |
|
BVA07 | 2459389-35-4 | |||||
18 | Azelastine Hydrochloride 盐酸氮卓斯汀 |
API | 79307-93-0 | 抗过敏 | USA -USDMF No. 036748 |
|
19 | Sitagliptin Phosphate 磷酸西格列汀 |
API | 654671-77-9 | 糖尿病 | China -CDE Registration No.:Y20200001086 登记状态:A |
|
20 | Tofacitinib Citrate 枸橼酸托法替布 |
TOF30 | 1062580-52-2 | 类风关 | PV Done | |
API | 540737-29-9 | China -CDE Registration No.:Y20210000971 登记状态:A |
||||
21 | Elagolix Sodium 艾拉戈克钠 |
API | 832720-36-2 | 子宫内膜异位症 | China -CDE Registration No.:Y20230000795 登记状态:I |
|
22 | SNAC | Carsalam卡沙兰 |
2037-95-8 | 合成SNAC | PV Done | |
Sodium 8-(2-hydroxybenzamido)octanoate(SNAC) | 203787-91-1 | 辅料 | PV Done | |||
23 | Methyl 3-oxovalerate 3-氧代戊酸甲酯 |
INT | 30414-53-0 | Commercial |
免责声明:受有效专利保护的产品不能销往构成侵犯专利的国家。上述专利保护产品仅供研发使用,并由买方承担全部责任。
搜索